New Weapons to Fight the Obesity Epidemic in XXI Century - Will They Fulfill the Promise?
The research on fat metabolism has made large progress over the last decade and has challenged several established views. One of the most important findings in recent obesity research was revealing that fat is an endocrine tissue (gland that secrets hormones in the body). Also, very important was the discovery of a number of peptides (short protein chains) that function as central regulators of food intake and energy metabolism. Such findings revealed that the neural and hormonal body systems are involved in complex interactions where the central nervous system (brain and the spinal cord) and fat communicate through hormones and neurotransmitters, and affect other organs.
The anti-obesity effect might be achieved by any of three basic approaches: a reduction in energy intake, a decrease in energy storage or an increase in energy expenditure. Each of them can be addressed by various specific mechanisms. With such perspectives one would expect the drug marked to be blooming. In reality, disregarding the advertising scams and marketing schemes, there is not much it the store today. And what is available is disappointingly far from perfect. In fact, all today available drugs and most of those in clinical development belong to the reduction in energy intake category and act either by appetite suppression or inhibition of intestinal absorption.
One class of drugs used to treat obesity today belongs to amphetamines (dextroamphetamine - Dexedrine), which are potent stimulants and can cause unacceptable tachycardia and hypertension. Other sympathomimetic adrenergic agents include: phentermine (Fastin), benzphetamine (Didrex), phendimetrazine (Bontril), mazindol (Sanorex), and diethylpropion (Tenuate). They have less abuse potential than amphetamines but these agents may have adverse cardiovascular side effects, and their indicated use is only short term (few weeks) [2].
Only two drugs are currently approved in the US for the long-term treatment of obesity: orlistat (Xenical) and sibutramine (Meridia). Sibutramine has an indication for treatment of obesity by primarily increasing satiety. Sibutramine-associated weight loss occurs within the first 6 months of treatment, may be maintained for at least 2 years, and may have favorable effects on coronary heart disease risk factors. Unfortunately, sibutramine's use is contraindicated in patients with uncontrolled hypertension, coronary heart disease, cardiac dysrhythmias, congestive heart failure, or stroke [3].
Orlistat is a gastrointestinal lipase inhibitor that impairs the absorption of dietary fat. Orlistat may improve lipid blood levels, improve glucose metabolism in obese patients and reduce high blood pressure [4]. Orlistat use frequently results in adverse events including flatus, oily stools, fecal urgency or fecal incontinence, and abdominal pain, particularly among patients who do not follow the recommended low-fat diet.
As the three major obesity drugs on the US market today: orlistat, sibutramine and phentermine have not satisfied the society requirements there are more compounds in the pharma cooking today. The most prominent include some new and promising approaches and are already in clinical trials. One developed by Sandofi-Aventis is already approved in the European Union - Rimonabant (Acomplia), and in clinical trials it was shown that 33% of people on Rimonabant lost 10% of body weight and kept their weight down for two years. This is a record, no other diet drug has managed to keep a person's weight down for so long. The drug also helps quit the smoking habit. Rimonabant blocks nerve receptors called CB1 cannabiniod receptors which tell the body to overeat (and also to intake nicotine) [5].
Among other anti-obesity drugs in clinical trials the Contrave from Orexigen is a combination of bupropion, a dopamine and norepinephrine reuptake inhibitor, with naltrexone, an opioid antagonist used to treat various addictive disorders [6]. It is believed that combining these two drugs may improve the ability to initiate weight loss, and importantly, to continue weight loss by blocking the body's attempts to compensate for weight loss during the treatment [7].
Alizyme company of UK works on compound named ALT-962 (Cetilistat). It is a Lipase inhibitor that inhibits gastric and pancreatic lipases in the the gastrointestinal tract to decrease absorption of dietary fat. It belongs to the same class of drugs as above described Orlistat, but it has less potency of inducing side effects [7].
The AOD9604 is a compound studied by Metabolic Pharmaceuticals of Australia. It is a peptide fragment of human growth hormone available orally and promoting lipid-metabolism, resulting in fat burning [7].
Vivus of Mountain View, CA is testing a combination of low doses of the active ingredients phentermine and topiramate (an anticonvulsant) under the name Qnexa. It is believed to affect both excessive hunger and the inability to feel satisfied [10].
Arena Pharmaceuticals of San Diego, CA developed APD-356 (Lorcaserin), which selectively stimulates the 5-HT2C serotonin receptor, located in the hypothalamus (an appetite control center of the brain) [7].
A new CB1 receptor antagonist (the same class as rimonabant) in trials is CP-945,598 developed by Pfizer. According to Pfizer it was well tolerated in Phase I trials and is one of their four CB-1 candidate medicines in development [7].
Amylin Pharmaceuticals of San Diego, CA runs clinical trials of Pramilitide a stable analog of Amylin, a peptide hormone that is co-secreted with insulin from the pancreatic ß-cell and is thus deficient in diabetic people. It inhibits glucagon secretion, delays gastric emptying, and acts as a satiety agent [8].
PYY(3-36) from Nastech of Bothell, WA is a naturally occurring human hormone released by cells in the intestine after meals. The amount secreted increases with the number of calories ingested and research has demonstrated the PYY has appetite suppressing function [7].
7TM Pharma of Denmark is developing TM30338, a synthetic analogue of both PYY(3-36) and PP (Pancreatic Polypeptide), which normally are released during a meal. Both these hormones are known to play a role in the regulation of food intake and appetite in man as satiety signals carried from the gastro-intestinal-tract to the brain [7].
These are just some of the most prominent candidates, however none of them brings the promise to effectively manage the worldwide epidemic of obesity. Nevertheless, the current medical research potential, with small and big research breakthroughs reported weekly, gives us rather strong feelings that the true medical help for obesity in near. By that time however we need to feel encouraged to change our lifestyle to move more and eat less. If you plan on loosing weight and beating your obesity problem you should first talk to your physician to get evaluation and professional guidance to do it safely and successfully. For some there might be quite a bit to loose in this game, but who would regret such loss in the end?
References:
1. Kopelman, P. G. (2000). Obesity as a medical problem. Nature, vol. 404, 635-643.
2. Ioannides-Demos, L. L., Proietto, J., Tonkin, A. M. & McNeil, J. J. (2006). Safety of drug therapies used for weight loss and treatment of obesity. Drug Safety, vol. 29, 277-302.
3. Kim, SH, Lee, YM, Jee, SH, Nam, CM. (2003). Effect of sibutramine on weight loss and blood pressure: a meta-analysis of controlled trials. Obes. Res., vol. 11, 1116-1123.
4. Rossner, S, Sjöström, L, Noack, R, Meinders, AE, Noseda, G. (2000). Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group. Obes. Res., vol. 8, 49-61.
5. Ravinet Trillou, C., Arnone, M., Delgorge, C., Gonalons, N., Keane, P., Maffrand, J-P. and Soubrié, P. (2003). Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am. J. Physiol. Regul. Integr. Comp. Physiol., vol. 284, 345-353.
6. Appolinario, J. C., Bueno, J. R. & Coutinho, W. (2004). Psychotropic drugs in the treatment of obesity: what promise? CNS Drugs, vol. 18, 629-651.
7. Dunstan Cooke and Steve Bloom. (2006). The obesity pipeline: current strategies in the development of anti-obesity drugs. Nature Reviews | Drug Discovery, vol. 5, 921-931.
8. Schmitz, O., Brock, B. and Rungby, J. (2004). Amylin Agonists: A Novel Approach in the Treatment of Diabetes. Diabetes, vol. 53, 233-238.
Related Tags: phentermine, obesity, fat, xenical, meridia, sibutramine, obesity treatment, orlistat, fastin, satiety
B. A. Kwiatkowski, Ph.D. has been involved in biomedical research for over twenty years and published several peer reviewed scientific articles in top biomedical journals. Recently he also writes popular health and medical research articles for BioMedClub (http://www.biomedclub.com). You may find more details concerning the new obesity treatments at: http://www.biomedclub.com/articles/
Your Article Search Directory : Find in ArticlesRecent articles in this category:
- Obesity Fact - 3 Causes Of Obesity
How many causes of obesity you know? If you are the one who over-weight and trying to lose weight, t - How To Get Rid Of Belly Fat - 5 Damn Easy Steps To Start Now!!
This is something no one wants really, but it's like "I can't help it" thing. Accumulating fat aroun - Obesity Is a Growing Problem
The number of overweight children ages 6 to 11 doubled in the last 20 years; in that same period, t - Never Too Early To Educate Your Child
Being a Wellness Educator I teach college students and train clients from ages 2 to 84. The fitness - Laparoscopic Obesity Surgery - How It Works and Can You Really Lose Weight With It
Laparoscopic obesity surgery is not a new term in weight loss, as a matter of fact you have probably - Mini Gastric Bypass Surgery Can Save your Life
Mini gastric bypass surgery is a frequent medical term that actually describes many similar kinds of - Espresso, Google and... Proactol
It was one of those days when I got up in the morning and had no willing to do my ordinary stuff. So - Gastric Bypass Information - What Exactly Is Gastric Bypass And How It Works
In the recent years you have probably heard quite a bit gastric bypass information, the term itself - Top 3 Reasons Why Your Kids are Fat
I love kids. Especially fat kids. They're like big teddy bears, nice to hold and hug. If I ever have - Food Intolerance and Obesity - It May Not Be Your Fault That You're Fat
As many as 80-90% of us have some form of adverse reaction to one or more foods or additives. Eating
Most viewed articles in this category:
- Boost Your Metabolism In Order To Lose Weighty
Perhaps you think that in order to lose weight you need to cut your calories way down. However, when - Overweight Children Need after School Activities
Is your child overweight? What does your child do when they come home from school? Have a snack and - Can eGovernment Help the Obese eCitizen Lose Weight by Providing Proper Information?
In the United States of America we have a weight problem, obesity challenge and it is reaching epide - Environmental Pollutants and Obesity
About four years ago at a health conference in Las Vegas, Nevada, I proposed a mechanism which expla - Risks of Obesity Cited as #1 Health Issue in 2020
According to Janet L. Bruno MD, an obesity expert, there are a number of diseases which are directly - Obesity is a Disease
Walking through a crowded shopping mall on a Saturday afternoon it's easy to notice that most Americ - Childhood Obesity Prevention Program Generates Instant and Delayed Gratification Simultaneously
Teaching kids to immunize themselves against obesity by teaching them to perform pull ups (obese kid - Obesity In Child
Strange things always seem to happen during the holidays. Our clothes shrink! And it seems like it - Re-Thinking Farming - The Solution To Obesity
World leaders need to force an end to 'crazy' agricultural policies that fuel the global obesity epi - Finally A Healthy Way To Lose Weight!
I know a lot of people make New Year's resolutions, but many people seem to fail at them. This past